Co-Diagnostics Inc.

AI Score

XX

Unlock

0.31
-0.01 (-4.02%)
At close: Apr 04, 2025, 11:38 AM

Company Description

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.

It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications.

The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings.

In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems.

The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Co-Diagnostics Inc.
Co-Diagnostics Inc. logo
Country United States
IPO Date Jul 12, 2017
Industry Medical - Devices
Sector Healthcare
Employees 132
CEO Dwight H. Egan

Contact Details

Address:
2401 South Foothill Drive
Salt Lake City, Utah
United States
Website https://www.codiagnostics.com

Stock Details

Ticker Symbol CODX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001692415
CUSIP Number 189763105
ISIN Number US1897631057
Employer ID 46-2609396
SIC Code 3841

Key Executives

Name Position
Dwight H. Egan Chairman & Chief Executive Officer
Christopher Thurston Chief Technology Officer
David Nielsen Chief Operating Officer
Andrew Benson Head of Investor Relations
Dan Bohrer CPA Vice President of Finance & Accounting
Dr. Mayuranki Almaula Ph.D. Senior Vice President of Overseas Operations & Strategic Alliances
Richard David Abbott President
Seth Egan Chief Commercialization Officer

Latest SEC Filings

Date Type Title
Mar 27, 2025 10-K Annual Report
Mar 27, 2025 8-K Current Report
Feb 21, 2025 8-K Current Report
Jan 10, 2025 8-K Current Report
Nov 25, 2024 4 Filing
Nov 25, 2024 4 Filing
Nov 25, 2024 4 Filing
Nov 25, 2024 4 Filing
Nov 25, 2024 4 Filing
Nov 25, 2024 4 Filing